Viemed Healthcare, Inc.

VMD

$9.01

+0.33%

2026-09-03 16:00:01 EDT+$0.03

Healthcare

Medical - Care Facilities

NASDAQ

Active Trading

Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company ...

Price Action of VMD

$9.01

+0.33%+$0.03

High—

Low—

52W High-28.5%

Rel. vol—

Interval

Range6.4h

Volume—SMA5SMA10

—

Viemed Healthcare, Inc. operates as a home medical equipment (HME) and post-acute respiratory healthcare services provider, headquartered in Lafayette, Louisiana. Founded in 2006 by Casey Hoyt and Michael Moore, the company has grown to become a key player in the respiratory care market. Viemed primarily focuses on respiratory disease management, ...Viemed Healthcare, Inc. operates as a home medical equipment (HME) and post-acute respiratory healthcare services provider, headquartered in Lafayette, Louisiana. Founded in 2006 by Casey Hoyt and Michael Moore, the company has grown to become a key player in the respiratory care market. Viemed primarily focuses on respiratory disease management, particularly for chronic obstructive pulmonary disease (COPD) and neuromuscular disorders, providing non-invasive and invasive ventilation, percussion vests, and other therapies. The company also offers a range of HME devices for rent or sale, including positive airway pressure (PAP) machines, oxygen concentrators, and durable medical equipment. Additionally, Viemed provides services such as in-home sleep apnea testing, breast pump fulfillment, and healthcare staffing and recruitment. With a workforce of approximately 1,382 employees, the company is committed to improving patient outcomes through 24/7 respiratory therapist support and dedicated treatment plans. Financially, Viemed has shown stable performance, with a market capitalization of around $370 million and a price-to-earnings ratio of about 25.8. The company operates with a gross profit margin of 57.2% and a net profit margin of 4.8%, reflecting its efficient service model. Under the leadership of CEO Casey Hoyt and President Michael Moore, Viemed continues to expand its reach, emphasizing innovative home-based care solutions and maintaining a strong focus on patient-centric services. The company is publicly traded on NASDAQ under the symbol VMD and continues to grow its footprint in the U.S. healthcare sector.ExpandCollapse

Founded

2006

Employees

1438

CEO

Casey Hoyt

Full Name

Viemed Healthcare, Inc.

Sector

Healthcare

Industry

Medical - Care Facilities

ROE

10.30%

Market Cap

$0.34B

Current Ratio

1.13

WACC

9.63%

ROIC

11.21%

Contact Information

https://www.viemed.com

337 504 3802

625 East Kaliste Saloom Road, Lafayette, LA 70508

Key Metrics of VMD

Snapshot

Latest / TTM · 6 periods

Market Cap

$343.17M

ROCE

15.7%

EV / EBITDA

6.42x

+3.8% YoY

FCF Yield

8.5%

+4.4% YoY

Cash Conversion Cycle

22.8d

Current Ratio

1.13

Quick take

TTM —

Positive CCC

Financial Highlights of VMD

Profitability trend

Latest / TTM · 6 periods

Gross Margin

57.2%

Net Margin

4.8%

P/E Ratio

23.89x

n/a

Debt / Equity

0.08

n/a

Current Ratio

1.13

Dividend Yield

0.0%

Understanding

TTM —

No major balance sheet stress in these headline ratios.

Calendar of VMD

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $0.12 · Revenue $80.78M · 2 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $0.15 · Revenue $83.49M · 2 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $0.41 · Revenue $317.94M · 2 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $0.10 · Revenue $82.88M · 1 analysts

Recent history

Aug 3, 2026
Q2 FY2026 · Results reported
EPS $0.07 · Revenue $78.10M
View filing
May 5, 2026
Q1 FY2026 · Results reported
EPS $0.06 · Revenue $75.41M
View filing
Mar 4, 2026
FY2025 · Annual results
EPS $0.37 · Revenue $270.28M
View filing
Nov 5, 2025
Q3 FY2025 · Results reported
EPS $0.09 · Revenue $71.91M
View filing
Aug 6, 2025
Q2 FY2025 · Results reported
EPS $0.08 · Revenue $63.06M
View filing
May 7, 2025
Q1 FY2025 · Results reported
EPS $0.06 · Revenue $59.13M
View filing

Financial Statements of VMD

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$270.3M	+20.5%	+3.6%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$14.9M	+32.6%	+7.0%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+57.5%	-3.2%	+1.6%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+7.7%	-4.0%	+3.4%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	+5.5%	+10.0%	+3.4%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$11.9M	+805.2%	+447.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+4.4%	+651.1%	+428.8%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	11.3%	+115.6%	-6.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	1.18x	-16.6%	-7.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$214.9M	+21.4%	+3.5%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	0.37 vs 0.40	-6.7%	0.07 vs 0.12	-41.7%
Revenue Surprise	$270.3M vs $272.0M	-0.6%	$78.1M vs $78.0M	+0.1%

Insider Transactions of VMD

Acquisitions (A)

Since Aug 19, 2026

Disposals (D)

Since Aug 19, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 19, 2026	Kaushal Nitin	director	Common Shares	A	18,786	—
Aug 19, 2026	Kaushal Nitin	director	Restricted Stock Units	D	18,786	—
Aug 19, 2026	Heltz Sabrina	director	Common Shares	A	3,757	—
Aug 19, 2026	Heltz Sabrina	director	Common Shares	A	15,029	—
Aug 19, 2026	Heltz Sabrina	director	Common Shares	D	3,757	$8.94

Earnings Call Transcript of VMD

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Greetings. Welcome to the Viemed Healthcare Second Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to Trae Fitzgerald, CFO. Thank you, Trae. You may begin. Trae Fitzgerald: Thank you, and good morning, everyone. Please note that our remarks in this conference call may include forward-looking statements under the U.S. federal securities laws or forward-looking information under applicable Canadian securities legislation, which we collectively refer to as forward-looking statements. Such statements reflect the company's current views and intentions with respect to future results or events and are subject to certain risks and uncertainties, which could cause actual results or events to vary from those indicated in forward-looking statements. Examples of such risks and uncertainties are discussed in our disclosure documents filed with the SEC or the security regulatory authorities in certain provinces of Canada. Because of these risks and uncertainties, investors should not produce undue reliance on forward-looking statements. The forward-looking statements made in this conference call are made as of today, and the company undertakes no obligations to update or revise any forward-looking statements, except as required by law. The second quarter financial supplement and financial news release as well as the related financial statements are available on the SEC's website. With that, I'll now turn the call over to our Chief Executive Officer, Casey Hoyt. Casey Hoyt: Okay. Thank you, Trae. Good morning, everyone, and thank you for joining us. I want to begin by recognizing the people responsible for our impressive Q2 results. As of June 30, we've got 1,453 employees that made up the Viemed team. Each day, our folks care for our patients, support our referral partners and improve how we operate. I appreciate their work, compassion and dedication they bring to serving our patients and our mission here at Viemed. The second quarter combined renewed growth in ventilation with continued expansion across the broader business. We ended June with the highest active ventilator patient count in our history, set new records in other service lines and generated record quarterly revenue. Ventilation remains the clinical and economic foundation for Viemed. For investors who are newer to the company, our vent patients live with complex chronic respiratory conditions and benefit from receiving high acuity care in the home. We combined respiratory therapy, ongoing clinical engagement and connected technology to help physicians manage those patients outside the hospital while improving their quality of life. We added 546 ventilator patients during the quarter and ended June with 12,635 active patients. The active patient count increased in each month of the quarter before accelerating in June, producing sequential growth of approximately 4.5%. Q2 produced the …

Leadership Team of VMD

8 executives

Name	Title	Compensation	Gender	Year Born	Status
Casey Hoyt	Chief Executive Officer & Director	USD 1,110,461	Male	1977	Active
Michael Moore	President	USD 973,488	Male	1977	Active
William Todd Zehnder	Chief Operating Officer & Director	USD 967,909	Male	1975	Active
Jerome Richard Cambre	Vice President of Sales	USD 553,003	Male	1971	Active
Jeremy Trahan	Executive VP, General Counsel & Corporate Secretary	USD 539,411	Male	1970	Active
Trae Paul Fitzgerald	Chief Financial Officer	USD 507,848	Male	1988	Active
William Dana Frazier	Chief Medical Officer & Director	USD 53,044	—	1958	Active
Michael Freeman	Chief Business Development Officer	—	Male	—	Active

Recent News of VMD

Seeking Alpha8/4/2026Neutral

Viemed Healthcare, Inc. (VMD) Q2 2026 Earnings Call Transcript

MarketBeat8/4/2026Neutral

Viemed Healthcare Q2 Earnings Call Highlights

Viemed Healthcare NASDAQ: VMD reported record second-quarter revenue as growth in its ventilator business resumed under the updated Medicare coverage framework and newer service lines expanded.

Zacks Investment Research8/3/2026Neutral

Viemed Healthcare, Inc. (VMD) Lags Q2 Earnings Estimates

Viemed Healthcare, Inc. (VMD) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.08 per share a year ago.

Accesswire8/3/2026Neutral

Viemed Healthcare Announces Second Quarter 2026 Financial Results

LAFAYETTE, LA / ACCESS Newswire / August 3, 2026 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, announced today that it has reported its financial results for the three and six months ended June 30, 2026, and updated guidance for the full year ending December 31, 2026. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended June 30, 2026 were $78.1 million, setting a Company record, representing an increase of $15.0 million, or 23.9%, compared with the prior-year quarter and an increase of approximately 3.6% sequentially.

Accesswire7/21/2026Neutral

Viemed Healthcare Announces Second Quarter 2026 Earnings Conference Call Details

LAFAYETTE, LA / ACCESS Newswire / July 21, 2026 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, today announced that it will host its Second Quarter 2026 Earnings Conference Call on Tuesday, August 4, 2026, at 11:00 a.m. EDT. Interested parties may participate in the call by dialing: 877-407-6176 (US Toll-Free) +1 201-689-8451 (International) Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=peVp8cbE Following the live call, a replay will be available in the Investor Relations section of the Company's website at www.viemed.com.

Historical Employee Count of VMD

Current

1,382

Change

+17.22%

Minimum

627

Maximum

1,382

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	1,382	10-K	Mar 4, 2026	View
Dec 31, 2024	1,179	10-K	Mar 10, 2025	View
Dec 31, 2023	996	10-K	Mar 6, 2024	View
Dec 31, 2022	743	10-K	Mar 2, 2023	View
Dec 31, 2021	627	10-K	Mar 7, 2022	View

Related stocksMedical - Care Facilities

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Viemed Healthcare, Inc.